Holen Sie sich die Stockscreener-App
1.45
1.39%
0.02
Bioxcel Therapeutics Inc Aktie (BTAI) Neueste Nachrichten
BioXcel Therapeutics $9.75M Class Action Settlement - Claim Depot
Levi & Korsinsky, LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of BioXcel Therapeutics, Inc. - GlobeNewswire Inc.
If You Invested $1,000 in Bioxcel Therapeutics Inc (BTAI) - Stock Titan
Stock Ratings | Baird Bank raises CRCL's price target to $138; Rodman & Renshaw initiates coverage of BTAI with a "buy" recommendation and a $17 price target, representing a potential upside of 882.66%. - Sahm
Why are BioXcel Therapeutics shares down Friday? - MSN
Why did BTAI stock surge 20% in pre-market today? - MSN
Buyout Rumor: Whats BioXcel Therapeutics Incs historical return2026 Trade Ideas & High Accuracy Swing Entry Alerts - baoquankhu1.vn
BioXcel Therapeutics Inc (BTAI) Stock Price, Quote, News & History - Benzinga
BioXcel Therapeutics stock initiated with buy rating at Rodman By Investing.com - Investing.com Canada
BioXcel Therapeutics stock initiated with buy rating at Rodman - Investing.com
BTAI: BioXcel Therapeutics Initiates Coverage with 'Buy' Rating - GuruFocus
This Ingredion Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
BioXcel Therapeutics (BTAI) CSO converts 68 RSUs into 6,520-share holding - Stock Titan
BioXcel Therapeutics (BTAI) officer converts 68 RSUs into common shares - Stock Titan
BioXcel Therapeutics (BTAI) CEO Vimal Mehta exercises RSUs for 383 shares - Stock Titan
BioXcel Therapeutics closes $8M registered direct offering - Investing.com Australia
Press Release: BioXcel Therapeutics Announces Closing of $8.0 Million Registered Direct Offering - 富途牛牛
How The BioXcel Therapeutics (BTAI) Story Is Shifting With Dilution Risks And Funding Needs - Yahoo Finance
BioXcel Therapeutics raises $8M in stock offering - Hartford Business Journal
BioXcel Therapeutics Announces Registered Direct Offering and Warrant Amendment – SEC 8-K Filing March 2026 - Minichart
BioXcel Therapeutics closes $8M registered direct offering By Investing.com - Investing.com South Africa
BioXcel Therapeutics Announces Registered Direct Equity Financing - TipRanks
BioXcel Therapeutics, Inc. Completes $8 Million Registered Direct Offering of Common Stock and Warrants - Quiver Quantitative
BioXcel Therapeutics Closes $8.0 Million Direct Offering - marketscreener.com
BioXcel Therapeutics (NASDAQ: BTAI) completes $7.8M equity and warrant financing - Stock Titan
BioXcel Therapeutics Announces Closing of $8.0 Million Registered Direct Offering - ChartMill
BioXcel Therapeutics raises $8M in registered direct offering - Investing.com Australia
BioXcel Therapeutics (NASDAQ: BTAI) raises ~$7.3M with 2.48M share offering - Stock Titan
BioXcel Therapeutics raises $8M in registered direct offering By Investing.com - Investing.com India
BioXcel Therapeutics Announces Approximately $8.0 Million Registered Direct Offering - The Manila Times
BioXcel raises $8M, reprices warrants in new share sale - Stock Titan
Aug Technicals: Is BioXcel Therapeutics Inc benefiting from interest rate changesQuarterly Risk Review & Safe Investment Capital Preservation Plans - baoquankhu1.vn
Bank of America Securities Sticks to Its Sell Rating for Bioxcel Therapeutics (BTAI) - The Globe and Mail
Why Are BioXcel Therapeutics Shares Down Friday? - Benzinga
BioXcel Therapeutics Announces Positive Phase 2 Topline Results from Columbia University-Led Study of BXCL501 for Treatment of Opioid Withdrawal - Sahm
BioXcel Therapeutics Seeks Market Expansion amid Financial Struggles - timothysykes.com
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
BioXcel Therapeutics Stock Soars Amid New Drug Approval Speculation - StocksToTrade
BTAI Stock Gained 5% TodayWhat's The Latest On Its Opioid Withdrawal Treatment? - Stocktwits
BioXcel Therapeutics (BTAI) Target Price Lowered by HC Wainwrigh - GuruFocus
BioXcel Therapeutics shares rise 2.7% as experimental opioid withdrawal drug shows benefit in mid-stage trial - marketscreener.com
BioXcel Therapeutics Achieves Milestone with Igalmi’s Market Study - timothysykes.com
BioXcel Therapeutics Stock Rallies Opioid Study Success - Benzinga
Why Did BTAI Stock Surge 20% In Pre-Market Today? - Asianet Newsable
BioXcel Therapeutics (BTAI) Reports Promising Phase 2 Results fo - GuruFocus
BTAI Stock Surges Pre-Market After On Positive Trial Results For Opioid Withdrawal Treatment - Stocktwits
BioXcel Therapeutics shares rise 21.1% premarket as experimental opioid withdrawal drug shows benefit in mid-stage trial - marketscreener.com
BioXcel Therapeutics rises amid sector rotation - Intellectia AI
Bioxcel Therapeutics announces positive Phase 2 topline results from Columbia University-led study of BXCL501 for treatment of opioid withdrawal - marketscreener.com
BioXcel reports positive Phase 2 data for opioid withdrawal drug By Investing.com - Investing.com UK
Bioxcel Therapeutics Announces Positive Phase 2 Topline Results From Columbia University-Led Study Of BXCL501 For Treatment Of Opioid Withdrawal - TradingView
Drug film BXCL501 eases opioid withdrawal in Columbia University study - Stock Titan
BTAI SEC FilingsBioxcel Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
BTAI PE Ratio & Valuation, Is BTAI Overvalued - Intellectia AI
BTAI Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
AI Drugmaker BioXcel Eyes $9.8M Investor Settlement - Law360
3.23%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):